Biotech company PrimeGen to go public through $1.5 billion SPAC deal
Biotechnology company PrimeGen US announced on Wednesday that it will go public in the United States through a $1.5 billion deal with blank check company DT Cloud Star Acquisition.
The transaction is expected to be completed in the second half of 2026. The merged company will operate under the name PrimeGen US and plans to be listed on the Nasdaq Stock Exchange.
This deal comes at a time when companies are showing renewed interest in going public through Special Purpose Acquisition Company (SPAC) mergers, viewing it as an alternative to traditional IPOs.
SPACs operate as shell companies, raising capital through an initial public offering (IPO) and subsequently merging with a privately held company to take it public.
PrimeGen is a biotechnology company focused on the development of stem cell therapies, primarily targeting treatments for acute liver injury and related critical illnesses.
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
HBAR trades below 20-day SMA as Hedera expands AI integration
The 5% Era of US Treasury Bonds Arrives: No Short-term "Explosions", but Pressure May Appear in 12 to 18 Months
The real impact of high interest rates lies in their duration. A large amount of debt issued at 2%-3% in 2020-2021 is now facing the pressure of being rolled over at a cost of 6%-8%, and this shock will concentrate and erupt in 12-18 months. The US housing market will bear the brunt, while commercial real estate, highly leveraged companies, and private equity-backed firms are also at serious risk. If high rates persist for more than half a year, the market’s tolerance will be completely exhausted.
FOMC Decision Today: Markets Price 92% Odds of a Hike to 3.75% – 4.00%
Crypto prices
More
